Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
Xiuning Le et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone et al.
NATURE MEDICINE (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
J. Lee et al.
Journal of Thoracic Oncology (2021)
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
Nasser K. Altorki et al.
LANCET ONCOLOGY (2021)
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer
Jamie E. Chaft et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima et al.
NATURE COMMUNICATIONS (2021)
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing
Ansam Sinjab et al.
CANCER DISCOVERY (2021)
Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.
Melba C. Jaramillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
Maria Casanova-Acebes et al.
NATURE (2021)
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Michael J. Grant et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
PD-L1 regulation revisited: impact on immunotherapeutic strategies
Giulia Lucibello et al.
TRENDS IN MOLECULAR MEDICINE (2021)
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer
Enrico Munari et al.
FRONTIERS IN IMMUNOLOGY (2021)
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Ben Sidders et al.
CLINICAL CANCER RESEARCH (2020)
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Sohyun Hwang et al.
SCIENTIFIC REPORTS (2020)
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu et al.
LANCET ONCOLOGY (2020)
Learning from clinical trials of neoadjuvant checkpoint blockade
Judith M. Versluis et al.
NATURE MEDICINE (2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
Khalid AbdulJabbar et al.
NATURE MEDICINE (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk et al.
NATURE MEDICINE (2020)
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Daniela Bruni et al.
NATURE REVIEWS CANCER (2020)
Immune evasion before tumour invasion in early lung squamous carcinogenesis
Celine Mascaux et al.
NATURE (2019)
A reality check of the accelerated approval of immune-checkpoint inhibitors
Jennifer Gill et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Julia Kargl et al.
JCI INSIGHT (2019)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H. Kadara et al.
ANNALS OF ONCOLOGY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Yonit Lavin et al.
CELL (2017)
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients
Edwin R. Parra et al.
CLINICAL CANCER RESEARCH (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer
Timothy R. Church et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
Apar Pataer et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer
Paul Roepman et al.
CLINICAL CANCER RESEARCH (2009)